Erica N. Bozeman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erica N. Bozeman has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jaina M. Patel
Department of Pathology, Emory University School of Medicine , Atlanta, Georgia, USA
2 shared publications - Periasamy Selvaraj
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
2 shared publications - Arun Krishnamoorthy
Duke University School of Medicine, Durham, NC
1 shared publication - Ashley Cimino-Mathews
Department of Pathology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA; Department of Oncology, The Johns Hopkins University School of Medicine, 401 N Broadway, Weinberg 2242, Baltimore, MD 21287, USA
1 shared publication - Danielle Daniels
Department of Pathology and Laboratory Medicine; Emory University School of Medicine; Atlanta, GA USA
1 shared publication - Deepa K. Machiah
Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, 30329
1 shared publication
Latest Publications
- Open Access
- 24 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (1) , 52-63
Allogeneic tumor cell vaccines
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.
- 24 September 2013
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 10 (1) , 52-63
Open AccessAllogeneic tumor cell vaccines
The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immunotherapies. The development of novel immunotherapies has been bolstered by the discovery of tumor-associated antigens (TAAs), through gene sequencing and proteomics. One such immunotherapy employs established allogeneic human cancer cell lines to induce antitumor immunity in patients through TAA presentation. Allogeneic cancer immunotherapies are desirable in a clinical setting due to their ease of production and availability. This review aims to summarize clinical trials of allogeneic tumor immunotherapies in various cancer types. To date, clinical trials have shown limited success due potentially to extensive degrees of inter- and intra-tumoral heterogeneity found among cancer patients. However, these clinical results provide guidance for the rational design and creation of more effective allogeneic tumor immunotherapies for use as monotherapies or in combination with other therapies.